European Respiratory Review最新文献

Background: Cystic fibrosis (CF) registries capture important information in high-burden health domains to support improvement in health outcomes, although a number of unanswered questions persist, as follows. 1) Do CF registries utilise implementation science strategies to improve patient outcomes? 2) Which implementation strategies have been engaged? 3) Has the engagement of these strategies been effective in improving clinical outcomes?

Methods: We undertook a systematic review to exploring the use of implementation science strategies by CF registries for healthcare improvement. We searched MEDLINE, Embase, Scopus, Emcare and Web of Science databases for use of Expert Recommendations for Implementing Change (ERIC) implementations and use of the Knowledge to Action framework for improvement. We used the Risk of Bias in Non-randomised Studies - of Interventions tool for risk-of-bias assessment.

Results: 1974 citations were identified and 12 studies included. Included studies described 45 ERIC implementation strategies from nine categories. Strategies included "use evaluative and iterative strategies" (n=9) and "develop stakeholder interrelationships" (n=10). Least-used strategies were "utilise financial strategies" (n=1), "support clinicians" category (n=3) and "provide interactive assistance" (n=2). All 12 studies utilised monitoring of knowledge use, and assessing barriers and facilitators of knowledge use. Only seven studies utilised mechanisms to sustain knowledge use.

Discussion: Reported studies describe significant benefits in important CF outcomes for people with CF reported at site-specific and population levels. Studies highlighted the importance of governance, leadership, patient and family engagement, multidisciplinary engagement, quality improvement, data and analytics and research. The ready availability of clinical performance data feedback to clinicians and patients by CF registries is likely to strengthen the effectiveness of CF registries in driving healthcare improvement within a learning health system.

The immune response to virus infection in the respiratory tract must be carefully balanced to achieve pathogen clearance without excessive immunopathology. For chronic respiratory diseases where there is ongoing inflammation, such as in asthma and COPD, airway immune balance is perturbed, and viral infection frequently worsens (exacerbates) these conditions. Reactive oxygen species (ROS) are critical to the induction and propagation of inflammation, and when appropriately regulated, ROS are vital cell signalling molecules and contribute to innate immunity. However, extended periods of high ROS concentration can cause excessive cellular damage that dysregulates antiviral immunity and promotes inflammation. Traditional antioxidant therapeutics have had limited success treating inflammatory diseases such as viral exacerbations of asthma or COPD, owing to nonspecific pharmacology and poorly understood pharmacokinetic properties. These drawbacks could be addressed with novel drug delivery technologies and pharmacological agents. This review summarises current research on ROS imbalances during virus infection, discusses the commercially available mitochondrial antioxidant drugs that have progressed to clinical trial and assesses novel drug delivery approaches for antioxidant delivery to the airways. Additionally, it provides a perspective on future research into pharmacological targeting of ROS for the treatment of respiratory virus infection and disease.

Pulmonary manifestations of systemic autoimmune rheumatic diseases (SARDs) may involve the large and small airways, lung parenchyma, pleura, respiratory muscles and thoracic cage. Bronchiolar disorders (BDs) or small airways disease (SAD) are common and may sometimes be the dominant presentation in patients with SARDs. We conducted a literature review using search terms "bronchiolitis," "small airway diseases" and the names of individual SARDs and collated relevant articles published between January 1977 and April 2024. A summary of the incidence/prevalence, clinical manifestations, pathogenetic mechanisms, pulmonary function testing, chest imaging, histopathology and treatment options for BDs associated with SARDs is provided in this review. BDs associated with Sjögren syndrome, rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, idiopathic inflammatory myositis, mixed connective tissue disease and ankylosing spondylitis are specifically highlighted.

Background: Quantitative lung ultrasound is increasingly being used in neonatology. The aim of this study is to identify the lung ultrasound scores (LUS) available for use in neonates, describe their characteristics and determine which LUS are most used and validated.

Methods: A systematic review of the literature was conducted following PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols extension for reporting literature searches in systematic reviews) guidelines. Articles describing LUS in newborn animals and human neonates, published up to March 2024, were searched in the PubMed and Embase databases.

Results: Out of 757 identified studies, 121 were included. Most of the articles were published in the past 5 years, predominantly by European investigators. They described 32 different LUS. Only 10 (31.4%) of these LUS had undergone at least one validation attempt and only 15 (48.4%) used the four-step scoring scale (i.e. scored from 0 to 3) based on classical lung ultrasound patterns originally described and well established in adult critical care medicine. The most common (49 (40.5%) of all the articles) neonatal score (published by Brat et al. in 2015) was based on this classical grading system. The most commonly used score was also validated using the greatest number of techniques and applied to all major neonatal respiratory disorders. Its simplified version is used to analyse six chest areas (anterior and lateral) to guide surfactant administration, while its extended version includes 10 areas by adding four posterior ones.

Conclusions: The most commonly used and validated score, consistent with adult critical care practice, should be the standard for assessing lung aeration in neonates.

Background: Health disparities are prevalent across respiratory diseases. Social determinants of health are closely associated with health disparities and account for between 30% and 55% of all health outcomes. In people with interstitial lung disease (ILD), disparities have the potential to significantly impact access to care and health outcomes along many stages of the disease journey.

Aim: This review aimed to provide an overview of health disparities in ILD, focusing on the determinants of health and access to care from diagnosis to end of life and to report on some approaches being proposed to address these disparities.

Methods: A narrative review of the literature was undertaken using three electronic databases (Ovid Embase, Medline and CINAHL) from inception to May 2024. Disparities and social determinants were mapped to the domains of the Dahlgren-Whitehead model of social determinants of health.

Results: A total of 31 studies were eligible for inclusion. Common disparities identified included differences in antifibrotic utilisation, representation in clinical trials, access to ILD care and lung transplantation waiting lists. Associated social determinants included race/ethnicity, gender, geography and socioeconomic status. Paradoxically, telehealth technology and utilisation have the potential to improve access to diagnostic and treatment options for marginalised communities but may exacerbate disparities for those with lower digital literacy and access.

Conclusion: Reducing health disparities in ILD will require an awareness and understanding of the root cause of the disparities at both the individual and societal level in order to develop effective interventions that improve access to care for all living with ILD.

Background: Pleural diseases represent a significant healthcare burden, affecting over 350 000 patients annually in the US alone and requiring accurate diagnostic approaches for optimal management. Traditional imaging techniques have limitations in differentiating various pleural disorders and invasive procedures are usually required for definitive diagnosis.

Methods: We conducted a nonsystematic, narrative literature review aimed at describing the latest advances in imaging techniques and artificial intelligence (AI) applications in pleural diseases.

Results: Novel ultrasound-based techniques, such as elastography and contrast-enhanced ultrasound, are described for their promising diagnostic accuracy in differentiating malignant from benign pleural lesions. Quantitative imaging techniques utilising pixel-density measurements to noninvasively distinguish exudative from transudative effusions are highlighted. AI algorithms, which have shown remarkable performance in pleural abnormality detection, malignant effusion characterisation and automated pleural fluid volume quantification, are also described. Finally, the role of deep-learning models in early complication detection and automated analysis of follow-up imaging studies is examined.

Conclusions: Advanced imaging techniques and AI applications show promise in the management and follow-up of pleural diseases, improving diagnostic accuracy and reducing the need for invasive procedures. However, larger prospective studies are needed for validation. The integration of AI-driven imaging analysis with molecular and genomic data offers potential for personalised therapeutic strategies, although challenges in data privacy, algorithm transparency and clinical validation persist. This comprehensive approach may revolutionise pleural disease management, enhancing patient outcomes through more accurate, noninvasive diagnostic strategies.

The ideal definition of asthma remission should be practical, measurable and meaningful for both patients and physicians, while also representing true disease modification. Unfortunately, current proposals to define asthma remission fall short of this standard, not for lack of careful consideration, but due to the challenges presented by asthma, including but not limited to variability in symptom perception, intrinsic variability in lung function, seasonality and the impact of comorbidities. This article discusses obstacles and challenges to developing a widely adopted, consensus definition of asthma remission. We searched the literature for keywords including "asthma", "remission" and "super-responder" and identified interventional trials in asthma that highlight the challenges inherent in defining asthma remission.

Background: Although there is agreement on surgically removing symptomatic congenital lung malformations (CLMs), the management of asymptomatic cases remains controversial. Some paediatric surgeons suggest conservative management for asymptomatic cases due to the low perceived risk of developing symptoms or malignancy. This study aimed to investigate the characteristics and management of adults with CLMs.

Methods: Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, a systematic review was conducted to find studies reporting on adult patients (aged ≥15 years) with CLMs.

Results: Out of 12 908 studies reviewed from 1947 to 2024, 653 studies met the inclusion criteria, covering 980 patients. None of the patients had a prenatal diagnosis. The mean±sd age at surgery was 39.4±15.7 years (range 15-86). A total of 74.4% of adults with CLMs presented with symptoms, leading to the detection of CLM. Pneumonia was the most common symptom in congenital pulmonary airway malformation (CPAM) and intralobar sequestration, with over 30% of these patients experiencing recurrent respiratory infections. In 11.7% of adults, CLMs harboured tumours at the time of surgical removal, with CPAM associated with lung tumours in over 20% of cases.

Conclusions: Thoracic surgeons recommend surgical resection for all adult CLM patients, including asymptomatic cases, due to risks of infections and malignancy. Conservative management was considered only when surgery was not feasible.